We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
RNA category is based on mRNA expression levels in the analyzed samples (RNA assay description). The categories include: tissue/cell line enriched, group enriched, tissue/cell line enhanced, expressed in all, mixed and not detected. RNA category is calculated separately for The Cancer Genome Atlas (TCGA) data from cancer tissues and internally generated Human Protein Atlas (HPA) data from normal tissues and cell lines.
TCGA (cancer tissue):
Expressed in all
HPA (cell line):
Expressed in all
HPA (normal tissue):
Expressed in all
Protein evidencei
Protein evidence scores are generated from several independent sources and are classified as evidence at i) protein level, ii) transcript level, iii) no evidence, or iv) not available.
Evidence at protein level
Protein expression normal tissuei
A summary of the overall protein expression pattern across the analyzed normal tissues. The summary is based on knowledge-based annotation.
"Estimation of protein expression could not be performed. View primary data." is shown for genes analyzed with a knowledge-based approach where available RNA-seq and gene/protein characterization data has been evaluated as not sufficient in combination with immunohistochemistry data to yield a reliable estimation of the protein expression profile.
Standardized explanatory sentences with additional information required for full understanding of the knowledge-based expression profile.
Antibody staining mainly not consistent with RNA expression data.
Reliability score - normal tissuesi
Reliability score (score description), divided into Enhanced, Supported, Approved, or Uncertain, is evaluated in normal tissues and based on consistency between antibody staining pattern, available RNA-Seq and gene/protein characterization data, as well as similarity between independent antibodies targeting the same protein.
Kaplan-Meier plots for all cancers where high expression of this gene has significant (p<0.001) association with patient survival are shown in this summary. Whether the prognosis is favourable or unfavourable is indicated in brackets. Each Kaplan-Meier plot is clickable and redirects to a detailed page that includes individual expression and survival data for patients with the selected cancer.
RNA expression overview shows RNA-seq data from The Cancer Genome Atlas (TCGA).
TCGA dataseti
RNA-seq data in 17 cancer types are reported as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA). RNA cancer tissue category is calculated based on mRNA expression levels across all 17 cancer tissues and include: cancer tissue enriched, cancer group enriched, cancer tissue enhanced, expressed in all, mixed and not detected. To access cancer specific RNA and prognostic data, click on the cancer name. The cancer types are color-coded according to which type of normal organ the cancer originates from.
Antibody staining in 20 different cancers is summarized by a selection of four standard cancer tissue samples representative of the overall staining pattern. From left: colorectal cancer, breast cancer, prostate cancer and lung cancer. An additional fifth image can be added as a complement. The assay and annotation is described here. Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.
For each cancer, color-coded bars indicate the percentage of patients (maximum 12 patients) with high and medium protein expression level. The cancer types are color-coded according to which type of normal organ the cancer originates from. Low or not detected protein expression results in a white bar. Mouse-over function shows details about expression level and normal tissue of origin. The images and annotations can be accessed by clicking on the cancer name or protein expression bar. If more than one antibody is analyzed, the tabs at the top of the staining summary section can be used to toggle between the different antibodies.
Rare case of lung, pancreatic and liver cancers displayed strong cytoplasmic staining with additional membranous positivity in few tissues. Several cases of prostate cancers along with few cases of melanomas, breast, ovarian and renal cancers were moderately positive. Remaining cancer tissues were weakly stained or negative.
Melanomas, ovarian and breast cancers showed moderate cytoplasmic positivity.
Remaining cancer tissues were weakly stained or negative.
GENE INFORMATIONi
Gene information from Ensembl and Entrez, as well as links to available gene identifiers are displayed here. Information was retrieved from Ensembl if not indicated otherwise.
Gene name
PTEN (HGNC Symbol)
Synonyms
BZS, MHAM, MMAC1, PTEN1, TEP1
Description
Phosphatase and tensin homolog (HGNC Symbol)
Entrez gene summary
This gene was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The protein encoded by this gene is a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway. The use of a non-canonical (CUG) upstream initiation site produces a longer isoform that initiates translation with a leucine, and is thought to be preferentially associated with the mitochondrial inner membrane. This longer isoform may help regulate energy metabolism in the mitochondria. A pseudogene of this gene is found on chromosome 9. Alternative splicing and the use of multiple translation start codons results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Feb 2015]
The protein browser displays the antigen location on the target protein(s) and the features of the target protein. The tabs at the top of the protein view section can be used to switch between the different splice variants to which an antigen has been mapped.
At the top of the view, the position of the antigen (identified by the corresponding HPA identifier) is shown as a green bar. A yellow triangle on the bar indicates a <100% sequence identity to the protein target.
Under the antigens, the maximum percent sequence identity of the protein to all other proteins from other human genes is displayed, using a sliding window of 10 aa residues (HsID 10) or 50 aa residues (HsID 50). The region with the lowest possible identity is always selected for antigen design, with a maximum identity of 60% allowed for designing a single-target antigen (read more).
The curve in blue displays the predicted antigenicity i.e. the tendency for different regions of the protein to generate an immune response, with peak regions being predicted to be more antigenic.The curve shows average values based on a sliding window approach using an in-house propensity scale. (read more).
If a signal peptide is predicted by a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius (turquoise) and/or transmembrane regions (orange) are predicted by MDM, these are displayed.
Low complexity regions are shown in yellow and InterPro regions in green. Common (purple) and unique (grey) regions between different splice variants of the gene are also displayed (read more), and at the bottom of the protein view is the protein scale.
PTEN-001
PTEN-005
PROTEIN INFORMATIONi
The protein information section displays alternative protein-coding transcripts (splice variants) encoded by this gene according to the Ensembl database.
The ENSP identifier links to the Ensembl website protein summary, while the ENST identifier links to the Ensembl website transcript summary for the selected splice variant. The data in the UniProt column can be expanded to show links to all matching UniProt identifiers for this protein.
The protein classes assigned to this protein are shown if expanding the data in the protein class column. Parent protein classes are in bold font and subclasses are listed under the parent class.
The Gene Ontology terms assigned to this protein are listed if expanding the Gene ontology column. The length of the protein (amino acid residues according to Ensembl), molecular mass (kDalton), predicted signal peptide (according to a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius) and the number of predicted transmembrane region(s) (according to MDM) are also reported.
P60484 [Direct mapping] Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN F6KD01 [Target identity:100%; Query identity:100%] Phosphatase and tensin-like protein; Phosphatase and tensin-like protein isoform A
Show all
Enzymes ENZYME proteins Hydrolases Predicted intracellular proteins Cancer-related genes Mutated cancer genes Mutational cancer driver genes COSMIC somatic mutations in cancer genes COSMIC Splicing Mutations COSMIC Somatic Mutations COSMIC Nonsense Mutations COSMIC Missense Mutations COSMIC Large Deletions COSMIC Germline Mutations COSMIC Frameshift Mutations Disease related genes Potential drug targets Protein evidence (Kim et al 2014) Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000079 [regulation of cyclin-dependent protein serine/threonine kinase activity] GO:0000287 [magnesium ion binding] GO:0001525 [angiogenesis] GO:0001933 [negative regulation of protein phosphorylation] GO:0002902 [regulation of B cell apoptotic process] GO:0004438 [phosphatidylinositol-3-phosphatase activity] GO:0004721 [phosphoprotein phosphatase activity] GO:0004722 [protein serine/threonine phosphatase activity] GO:0004725 [protein tyrosine phosphatase activity] GO:0005161 [platelet-derived growth factor receptor binding] GO:0005515 [protein binding] GO:0005576 [extracellular region] GO:0005634 [nucleus] GO:0005654 [nucleoplasm] GO:0005737 [cytoplasm] GO:0005739 [mitochondrion] GO:0005829 [cytosol] GO:0005886 [plasma membrane] GO:0006470 [protein dephosphorylation] GO:0006629 [lipid metabolic process] GO:0006661 [phosphatidylinositol biosynthetic process] GO:0006915 [apoptotic process] GO:0007270 [neuron-neuron synaptic transmission] GO:0007399 [nervous system development] GO:0007416 [synapse assembly] GO:0007417 [central nervous system development] GO:0007507 [heart development] GO:0007568 [aging] GO:0007584 [response to nutrient] GO:0007611 [learning or memory] GO:0007613 [memory] GO:0007626 [locomotory behavior] GO:0008138 [protein tyrosine/serine/threonine phosphatase activity] GO:0008283 [cell proliferation] GO:0008284 [positive regulation of cell proliferation] GO:0008285 [negative regulation of cell proliferation] GO:0008289 [lipid binding] GO:0009749 [response to glucose] GO:0009898 [cytoplasmic side of plasma membrane] GO:0010033 [response to organic substance] GO:0010035 [response to inorganic substance] GO:0010043 [response to zinc ion] GO:0010975 [regulation of neuron projection development] GO:0010997 [anaphase-promoting complex binding] GO:0014067 [negative regulation of phosphatidylinositol 3-kinase signaling] GO:0014070 [response to organic cyclic compound] GO:0016311 [dephosphorylation] GO:0016314 [phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity] GO:0016324 [apical plasma membrane] GO:0016477 [cell migration] GO:0016579 [protein deubiquitination] GO:0016605 [PML body] GO:0016787 [hydrolase activity] GO:0016791 [phosphatase activity] GO:0019899 [enzyme binding] GO:0019901 [protein kinase binding] GO:0021542 [dentate gyrus development] GO:0021955 [central nervous system neuron axonogenesis] GO:0030165 [PDZ domain binding] GO:0030336 [negative regulation of cell migration] GO:0030534 [adult behavior] GO:0031175 [neuron projection development] GO:0031642 [negative regulation of myelination] GO:0031647 [regulation of protein stability] GO:0031658 [negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle] GO:0032228 [regulation of synaptic transmission, GABAergic] GO:0032286 [central nervous system myelin maintenance] GO:0032355 [response to estradiol] GO:0032535 [regulation of cellular component size] GO:0033032 [regulation of myeloid cell apoptotic process] GO:0033198 [response to ATP] GO:0033555 [multicellular organismal response to stress] GO:0035176 [social behavior] GO:0035335 [peptidyl-tyrosine dephosphorylation] GO:0035749 [myelin sheath adaxonal region] GO:0036294 [cellular response to decreased oxygen levels] GO:0042493 [response to drug] GO:0042711 [maternal behavior] GO:0042802 [identical protein binding] GO:0042995 [cell projection] GO:0043005 [neuron projection] GO:0043065 [positive regulation of apoptotic process] GO:0043066 [negative regulation of apoptotic process] GO:0043197 [dendritic spine] GO:0043220 [Schmidt-Lanterman incisure] GO:0043491 [protein kinase B signaling] GO:0043542 [endothelial cell migration] GO:0043647 [inositol phosphate metabolic process] GO:0045211 [postsynaptic membrane] GO:0045471 [response to ethanol] GO:0045475 [locomotor rhythm] GO:0045792 [negative regulation of cell size] GO:0046621 [negative regulation of organ growth] GO:0046685 [response to arsenic-containing substance] GO:0046855 [inositol phosphate dephosphorylation] GO:0046856 [phosphatidylinositol dephosphorylation] GO:0048008 [platelet-derived growth factor receptor signaling pathway] GO:0048015 [phosphatidylinositol-mediated signaling] GO:0048679 [regulation of axon regeneration] GO:0048681 [negative regulation of axon regeneration] GO:0048738 [cardiac muscle tissue development] GO:0048853 [forebrain morphogenesis] GO:0048854 [brain morphogenesis] GO:0050680 [negative regulation of epithelial cell proliferation] GO:0050765 [negative regulation of phagocytosis] GO:0050771 [negative regulation of axonogenesis] GO:0050821 [protein stabilization] GO:0050852 [T cell receptor signaling pathway] GO:0051091 [positive regulation of sequence-specific DNA binding transcription factor activity] GO:0051717 [inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity] GO:0051726 [regulation of cell cycle] GO:0051800 [phosphatidylinositol-3,4-bisphosphate 3-phosphatase activity] GO:0051895 [negative regulation of focal adhesion assembly] GO:0051898 [negative regulation of protein kinase B signaling] GO:0060024 [rhythmic synaptic transmission] GO:0060044 [negative regulation of cardiac muscle cell proliferation] GO:0060070 [canonical Wnt signaling pathway] GO:0060074 [synapse maturation] GO:0060134 [prepulse inhibition] GO:0060179 [male mating behavior] GO:0060291 [long-term synaptic potentiation] GO:0060292 [long term synaptic depression] GO:0060341 [regulation of cellular localization] GO:0060736 [prostate gland growth] GO:0060997 [dendritic spine morphogenesis] GO:0061002 [negative regulation of dendritic spine morphogenesis] GO:0070373 [negative regulation of ERK1 and ERK2 cascade] GO:0070374 [positive regulation of ERK1 and ERK2 cascade] GO:0071456 [cellular response to hypoxia] GO:0090071 [negative regulation of ribosome biogenesis] GO:0090344 [negative regulation of cell aging] GO:0090394 [negative regulation of excitatory postsynaptic potential] GO:0097105 [presynaptic membrane assembly] GO:0097107 [postsynaptic density assembly] GO:1903984 [positive regulation of TRAIL-activated apoptotic signaling pathway] GO:1904668 [positive regulation of ubiquitin protein ligase activity] GO:1990381 [ubiquitin-specific protease binding] GO:2000060 [positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process] GO:2000134 [negative regulation of G1/S transition of mitotic cell cycle] GO:2000463 [positive regulation of excitatory postsynaptic potential] GO:2000808 [negative regulation of synaptic vesicle clustering] GO:2001235 [positive regulation of apoptotic signaling pathway]
The Human Protein Atlas project is funded
MENU
